DYN vs. ARWR, DRNA, RNA, PTGX, AMPH, VTRS, SRPT, RDY, INSM, and LEGN
Should you be buying Dyne Therapeutics stock or one of its competitors? The main competitors of Dyne Therapeutics include Arrowhead Pharmaceuticals (ARWR), Dicerna Pharmaceuticals (DRNA), Avidity Biosciences (RNA), Protagonist Therapeutics (PTGX), Amphastar Pharmaceuticals (AMPH), Viatris (VTRS), Sarepta Therapeutics (SRPT), Dr. Reddy's Laboratories (RDY), Insmed (INSM), and Legend Biotech (LEGN). These companies are all part of the "medical" sector.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Dyne Therapeutics (NASDAQ:DYN) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.
Arrowhead Pharmaceuticals received 513 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. However, 76.00% of users gave Dyne Therapeutics an outperform vote while only 65.36% of users gave Arrowhead Pharmaceuticals an outperform vote.
Arrowhead Pharmaceuticals currently has a consensus target price of $43.25, suggesting a potential upside of 53.42%. Dyne Therapeutics has a consensus target price of $43.11, suggesting a potential downside of 3.19%. Given Dyne Therapeutics' higher probable upside, research analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Dyne Therapeutics.
Arrowhead Pharmaceuticals has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.
Arrowhead Pharmaceuticals has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Dyne Therapeutics has a net margin of 0.00% compared to Dyne Therapeutics' net margin of -163.32%. Arrowhead Pharmaceuticals' return on equity of -110.92% beat Dyne Therapeutics' return on equity.
In the previous week, Arrowhead Pharmaceuticals had 16 more articles in the media than Dyne Therapeutics. MarketBeat recorded 20 mentions for Arrowhead Pharmaceuticals and 4 mentions for Dyne Therapeutics. Arrowhead Pharmaceuticals' average media sentiment score of 1.14 beat Dyne Therapeutics' score of 0.61 indicating that Dyne Therapeutics is being referred to more favorably in the news media.
62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 4.5% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 20.8% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Dyne Therapeutics beats Arrowhead Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Dyne Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dyne Therapeutics Competitors List
Related Companies and Tools
